Development and use of FRAX® in osteoporosis
This paper reviews briefly the development and clinical use of FRAX® in the development of assessment guidelines for osteoporosis.
Fractures are the clinical consequence of osteoporosis and are a major cause of morbidity and mortality worldwide. Several treatments are available that have been shown to decrease the risk of fracture, but problems arise in identifying individuals at high fracture risk so that treatments can be effectively targeted. Case finding can be enhanced by the consideration of clinical risk factors that provide information on fracture risk over and above that provided by bone mineral density measurements. The FRAX tool integrates information on fracture risk from clinical risk factors with or without the use of BMD and can be used to improve the targeting of individuals at high fracture risk.
KeywordsCase finding Clinical guidelines Fracture probability FRAX Intervention threshold
- 1.Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UKGoogle Scholar
- 26.Johansson H, Kanis JA, Borgström F, Ström O, Svensson O, Mellström D (2010) FRAX® ett stöd för frakturprevention. Läkartidningen, in pressGoogle Scholar
- 27.Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, LondonGoogle Scholar
- 28.Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Update on pharmacological interventions and an algorithm for management. Royal College of Physicians, London, UKGoogle Scholar
- 29.Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians, London, UKGoogle Scholar
- 31.Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256Google Scholar
- 33.National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Society of Rheumatology, Society of Endocrinology, British Orthopaedic Association, Primary Care Rheumatology Society, Osteoporosis 2000 and Osteoporosis Dorset (2008) Osteoporosis: clinical guideline for prevention and treatment. University of Sheffield Press, SheffieldGoogle Scholar
- 38.National Osteoporosis Foundation (NOF) (2008) Clinician’s Guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, National Osteoporosis Foundation Washington www.nof.org
- 40.Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London, CHMPGoogle Scholar
- 42.Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®. Bone 44:49–54Google Scholar